TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24963566

Group type: EXPERIMENTAL
Intervention: 30-day event-triggered recorder (intervention group)
Number of subjects: 572

Group type: COMPARATOR
Intervention: Conventional 24-hour monitor (control group)
Number of subjects: 572
Study: 21916811

Group type: EXPERIMENTAL
Intervention: CTG+Doppler
Number of subjects: 256

Group type: COMPARATOR
Intervention: CTG
Number of subjects: 256
Study: 18556619

Group type: EXPERIMENTAL
Intervention: Enhanced patient-based partner notification
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard-of-care group
Number of subjects: 600
Study: 17650791

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 7422

Group type: COMPARATOR
Intervention: Previous RCTs (1980-1998)
Number of subjects: 7422
Study: 15200542

Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bonfils intubation fibrescope
Number of subjects: 80
Study: 12217071

Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Flexibility program
Number of subjects: 40
Study: 9690805

Group type: EXPERIMENTAL
Intervention: Morning subcutaneous administration of 5000 IU dalteparin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Evening subcutaneous administration of 5000 IU dalteparin
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of 5000 IU dalteparin
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of 2500 IU dalteparin
Number of subjects: 17
Study: 8088043

Group type: EXPERIMENTAL
Intervention: Erect position (sitting or ambulant)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Decubitus position (right side down)
Number of subjects: 105
Study: 2758260

Group type: EXPERIMENTAL
Intervention: Mastectomy and axillary clearance (40 women)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Mastectomy and axillary sampling (54 women)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (28 women with axillary nodal metastasis)
Number of subjects: 94

Group type: COMPARATOR
Intervention: No adjuvant radiotherapy (26 women without axillary nodal metastasis)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 94
Study: 796939

Group type: EXPERIMENTAL
Intervention: Ketoprofen 200 mg daily for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Phenylbutazone 300 mg daily for 4 weeks
Number of subjects: 20
Study: 31444669

Group type: EXPERIMENTAL
Intervention: Low-frequency sonophoresis of Chinese medicine (LFS/CM) combined with intrapleural IL-2
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Low-frequency sonophoresis of Chinese medicine (LFS/CM)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Intravenous administration of IL-2 (control group)
Number of subjects: 110
Study: 30528639

Group type: EXPERIMENTAL
Intervention: Higher physical fatigability (≥ 15)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Higher mental fatigability (≥ 13)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both higher physical and mental fatigability
Number of subjects: 29
Study: 28279950

Group type: EXPERIMENTAL
Intervention: InsuOnline electronic game intervention
Number of subjects: 134

Group type: COMPARATOR
Intervention: Traditional CME session
Number of subjects: 134
Study: 25919754

Group type: EXPERIMENTAL
Intervention: Person-centred care intervention
Number of subjects: 199

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 199
Study: 22961727

Group type: EXPERIMENTAL
Intervention: Glycerol phenylbutyrate
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sodium phenylbutyrate (NaPBA)
Number of subjects: 65
Study: 21402981

Group type: EXPERIMENTAL
Intervention: Order of IOP measurement starting with right eye
Number of subjects: 105

Group type: COMPARATOR
Intervention: Order of IOP measurement starting with left eye
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: First visit measurements
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Right eye measurements
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Ocular squeezing
Number of subjects: 105
Study: 19277472

Group type: EXPERIMENTAL
Intervention: KKS Network support for clinical trials
Number of subjects: 0
Study: 17886213

Group type: EXPERIMENTAL
Intervention: Monotherapy with ACE‐i
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Monotherapy with ARB
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Combined treatment with ACE‐i + ARB
Number of subjects: 2100
Study: 14996515

Group type: EXPERIMENTAL
Intervention: Epinastine hydrochloride 0.05% ophthalmic solution, 1 drop/eye BID for 8 weeks
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Levocabastine hydrochloride 0.05% ophthalmic suspension, 1 drop/eye BID for 8 weeks
Number of subjects: 298

Group type: COMPARATOR
Intervention: Vehicle of epinastine, 1 drop/eye BID for 8 weeks
Number of subjects: 298
Study: 11795349

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0

Group type: COMPARATOR
Intervention: HRT
Number of subjects: 0
Study: 9043840

Group type: EXPERIMENTAL
Intervention: Antianginal therapy (nitrates and calcium antagonists)
Number of subjects: 26
Study: 7884660

Group type: EXPERIMENTAL
Intervention: TY‐11345 (40 mg single dose)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: TY‐11345 (20 mg single dose)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: TY‐11345 (60 mg repeated dose)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: TY‐11345 (40 mg single dose with food)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: TY‐11345 (20, 40, and 80 mg single doses)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: TY‐11345 (all doses)
Number of subjects: 2
Study: 3124674

Group type: EXPERIMENTAL
Intervention: 60 mg terfenadine twice daily
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: 4 mg chlorpheniramine three times daily
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 30176758

Group type: EXPERIMENTAL
Intervention: Intrauterine misoprostol (400 mg) added to oxytocin
Number of subjects: 300

Group type: COMPARATOR
Intervention: Routine oxytocin alone
Number of subjects: 300
Study: 30782151

Group type: EXPERIMENTAL
Intervention: Delirium Observation Screening Scale (DOS)
Number of subjects: 193
Study: 28596192

Group type: EXPERIMENTAL
Intervention: Conscious Sedation
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: General Anesthesia
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conscious Sedation and General Anesthesia
Number of subjects: 104
Study: 26300016

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) 0.3 g.kg(‐1) body weight
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (dextrose)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3)
Number of subjects: 15
Study: 23273683

Group type: EXPERIMENTAL
Intervention: Thoracic epidural infusion (PERI group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous local wound infiltration (LOC group)
Number of subjects: 60
Study: 21664026

Group type: EXPERIMENTAL
Intervention: Simulation-based educational program (4 simulation scenarios in a 6h education session)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 31
Study: 18536698

Group type: EXPERIMENTAL
Intervention: Tolcapone 200 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 16849754

Group type: EXPERIMENTAL
Intervention: 2 g EPA
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: 4 g EPA
Number of subjects: 518

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518
Study: 12845488

Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg/day orally for 5 days
Number of subjects: 55

Group type: COMPARATOR
Intervention: Low-iodine diet for 14 days
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 55

Group type: COMPARATOR
Intervention: Low-iodine diet
Number of subjects: 55
Study: 10759443

Group type: EXPERIMENTAL
Intervention: Biphasic positive airway pressure (BiPAP) at 15 cmH2O Phigh and 5 cmH2O Plow
Number of subjects: 21

Group type: COMPARATOR
Intervention: Pressure support (PS) at 15 cmH2O
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Biphasic positive airway pressure (BiPAP) during Plow phases
Number of subjects: 21

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP) at 5 cmH2O
Number of subjects: 21
Study: 8810812

Group type: EXPERIMENTAL
Intervention: PTCCP (Percutaneous transhepatic cholecyst puncture)
Number of subjects: 35

Group type: COMPARATOR
Intervention: PTCCD (Percutaneous transhepatic cholecyst drainage)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conservative treatment (antibiotics administration)
Number of subjects: 35
Study: 1419940

Group type: EXPERIMENTAL
Intervention: 10 micrograms sufentanil
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 15 micrograms sufentanil
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 20 micrograms sufentanil
Number of subjects: 37

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: All sufentanil groups
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 37
Study: 3907376

Group type: EXPERIMENTAL
Intervention: Ceruletide
Number of subjects: 0
Study: 30939537

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (o-CEE)
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Transdermal 17Î²-estradiol (t-E2)
Number of subjects: 727

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 727
Study: 30341117

Group type: EXPERIMENTAL
Intervention: Single FMT dose
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Five daily FMT doses
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no FMT dose)
Number of subjects: 30
Study: 27150723

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (one face-to-face contact and one phone contact with the interventionist)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 140
Study: 24534225

Group type: EXPERIMENTAL
Intervention: NPSRH
Number of subjects: 83

Group type: COMPARATOR
Intervention: CRH
Number of subjects: 83
Study: 22966104

Group type: EXPERIMENTAL
Intervention: Outreach intervention (direct mailing of FOBT kits and colorectal cancer fact sheet)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Usual care (referral for screening during clinician visits)
Number of subjects: 202
Study: 20560847

Group type: EXPERIMENTAL
Intervention: Internet-based clinician-assisted cognitive behavioural treatment program (the Panic program)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 59
Study: 16900557

Group type: EXPERIMENTAL
Intervention: Biologic treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy or placebo
Number of subjects: 0
Study: 16195955

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 75

Group type: COMPARATOR
Intervention: Drug-free Baseline session
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Later sessions (regardless of drug condition)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Methylphenidate (for Combined subtype)
Number of subjects: 75
Study: 11824858

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no antihypertensive therapy)
Number of subjects: 80
Study: 10511835

Group type: EXPERIMENTAL
Intervention: Classroom-based intervention
Number of subjects: 2109

Group type: EXPERIMENTAL
Intervention: Risk-based intervention
Number of subjects: 2109

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2109
Study: 8523056

Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa-2a (rIFN alpha-2a) at 3 million units (MU)/m2 subcutaneously three times per week, escalated to 9 MU/m2 as tolerated.
Number of subjects: 171

Group type: COMPARATOR
Intervention: Observation alone (control group).
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa-2a (rIFN alpha-2a).
Number of subjects: 171
Study: 2287905

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Cephradine
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control
Number of subjects: 179
Study: 7317249

Group type: EXPERIMENTAL
Intervention: Atropine 20 micrograms kg‐1
Number of subjects: 50

Group type: COMPARATOR
Intervention: Glycopyrrolate 10 micrograms kg‐1
Number of subjects: 50
Study: 30547704

Group type: EXPERIMENTAL
Intervention: TAVI (Transcatheter Aortic Valve Implantation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study: 30170643

Group type: EXPERIMENTAL
Intervention: Walnut diet
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Almond diet
Number of subjects: 27
Study: 26940027

Group type: EXPERIMENTAL
Intervention: ICECAP-A
Number of subjects: 0

Group type: COMPARATOR
Intervention: EQ-5D-3 L
Number of subjects: 0
Study: 24738803

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (n = 62)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Epidural (n = 53)
Number of subjects: 115
Study: 22409383

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 19155827

Group type: EXPERIMENTAL
Intervention: Saline washout
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Commercially available acidic washout solution (Contisol)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Usual care (no washout)
Number of subjects: 73
Study: 17999011

Group type: EXPERIMENTAL
Intervention: High-intensity strength training of non-operated limb for 3 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Regular-intensity strength training of non-operated limb for 3 weeks
Number of subjects: 62
Study: 15021311

Group type: EXPERIMENTAL
Intervention: IFN alfa-2b 3 mIU daily plus RBV 800 mg/d
Number of subjects: 180

Group type: COMPARATOR
Intervention: IFN alfa-2b 3 mIU thrice weekly plus RBV 800 mg/d
Number of subjects: 180
Study: 11825138

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support program
Number of subjects: 219

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 219
Study: 10729968

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ice massage
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 8835361

Group type: EXPERIMENTAL
Intervention: FPL 64170XX 0.5% enema
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 2257959

Group type: EXPERIMENTAL
Intervention: 10% naproxen gel
Number of subjects: 30

Group type: COMPARATOR
Intervention: 10% ketoprofen gel
Number of subjects: 30
Study: 519265

Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy (streptokinase)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Control group (no fibrinolytic therapy)
Number of subjects: 315
Study: 31187186

Group type: EXPERIMENTAL
Intervention: Coated activated charcoal hemoperfusion (CAC-HP) for 4 hours followed by a 1-hour redistribution phase
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no CAC-HP)
Number of subjects: 14
Study: 25993298

Group type: EXPERIMENTAL
Intervention: Supervised exercise (IC-Ex) for 12 months
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual care (IC-Con)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (healthy adults)
Number of subjects: 31
Study: 23676183

Group type: EXPERIMENTAL
Intervention: CETP inhibitor
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 21428792

Group type: EXPERIMENTAL
Intervention: Recommendation from a clinician to get mammography
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Recommendation from a clinician to get Pap smears
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Current health insurance and a visit with healthcare provider in the past year
Number of subjects: 504
Study: 19396791

Group type: EXPERIMENTAL
Intervention: 1.25 mg intracameral bevacizumab (Group 1)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 2.5 mg intracameral bevacizumab (Group 2)
Number of subjects: 19
Study: 16525571

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Eptifibatide plus unfractionated heparin
Number of subjects: 30
Study: 10867972

Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 30
Study: 8778949

Group type: EXPERIMENTAL
Intervention: Active Behçet's disease patients
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Inactive Behçet's disease patients
Number of subjects: 63

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Behçet's disease patients (active and inactive)
Number of subjects: 63
Study: 1764349

Group type: EXPERIMENTAL
Intervention: Acupuncture (needles inserted into Hegu plus Shousanli, Hegu plus Waiguan, or Shousanli positions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tactile skin stimulation (applied to the ulnar side of the palm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tactile skin stimulation (applied to the dorsal surface of the hand or forearm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupuncture and tactile stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tactile skin stimulation
Number of subjects: 0
Study: 6363670

Group type: EXPERIMENTAL
Intervention: Gentamicin, ampicillin, and clindamycin (GAC)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Gentamicin, ampicillin, and placebo (GAP)
Number of subjects: 64
Study: 31215174

Group type: EXPERIMENTAL
Intervention: PA+C group (MoVo-work program including a PA component and a coaching component)
Number of subjects: 213

Group type: COMPARATOR
Intervention: PA group (only the PA component)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: PA+C group
Number of subjects: 213

Group type: COMPARATOR
Intervention: PA group
Number of subjects: 213
Study: 30146709

Group type: EXPERIMENTAL
Intervention: BTL UNISON device treatments (4 sessions)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no treatments)
Number of subjects: 46
Study: 27315134

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 800mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1600mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 2000mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 2400mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alprazolam (ALP) 1.5mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alprazolam (ALP) 3.0mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) (all doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alprazolam (ALP)
Number of subjects: 0
Study: 24951108

Group type: EXPERIMENTAL
Intervention: Dietitian-delivered lifestyle modification intervention
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Home-based interventions, communication in the participant's chosen language(s), continuity in dietitians
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dietary and exercise recommendations
Number of subjects: 24
Study: 23306858

Group type: EXPERIMENTAL
Intervention: Cyclic loading at 45° to the long axis of the teeth of 127.4 N at a 6 Hz frequency
Number of subjects: 44

Group type: COMPARATOR
Intervention: No cyclic loading (Control)
Number of subjects: 44
Study: 19853399

Group type: EXPERIMENTAL
Intervention: 2 hours of disease-specific education delivered by a certified COPD educator
Number of subjects: 93

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 93
Study: 17984433

Group type: EXPERIMENTAL
Intervention: 3.86% glucose, low pH/high GDP dialysis solution (pH 5.5)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 3.86% glucose, normal pH/low GDP dialysis solution (pH 7.4)
Number of subjects: 10
Study: 15711977

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) ventilation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure (BIPAP) ventilation
Number of subjects: 10
Study: 12413989

Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 73

Group type: COMPARATOR
Intervention: Standard IVF (0.2 x 10(6)/mL)
Number of subjects: 73

Group type: COMPARATOR
Intervention: HIC IVF (0.8 x 10(6)/mL)
Number of subjects: 73
Study: 10446037

Group type: EXPERIMENTAL
Intervention: 400 mg/day of alpha-tocopherol
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 7796786

Group type: EXPERIMENTAL
Intervention: 30 mg/day zinc gluconate for 3 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 22
Study: 31918557

Group type: EXPERIMENTAL
Intervention: Mini-mesh and Lichtenstein repair (M group)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Modified Kugel repair (K group)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 97
Study: 30430745

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP) using either two bottles of sodium phosphate or 2-L polyethylene glycol
Number of subjects: 122

Group type: COMPARATOR
Intervention: No mechanical bowel preparation (no-MBP)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 122
Study: 28561902

Group type: EXPERIMENTAL
Intervention: Rapid BDM (ready-to-dilute solution, 50 mL admixture, infusion time 10 minutes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Original BDM (lyophilized product requiring reconstitution, 500 mL admixture, infusion time 30 or 60 minutes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both BDM formulations
Number of subjects: 0
Study: 25132206

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 35
Study: 24621834

Group type: EXPERIMENTAL
Intervention: Intravenous levosimendan for 24 hours
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Intravenous levosimendan
Number of subjects: 700